Now showing items 11-20 of 41
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection.
(U.S. National Center for Infectious Diseases., 2013-03)
High mortality rates have been reported for patients co-infected with extensively drug-resistant tuberculosis (XDR-TB) and HIV, but treatment outcomes have not been reported. We report treatment outcomes for adult XDR TB ...
Pulmonary resection for extensively drug resistant tuberculosis in KwaZulu-Natal, South Africa.
Background—Extensively-drug resistant tuberculosis (XDR-TB) has been reported in 58 countries around the world and has emerged as a major public health challenge. This is the first report to describe pulmonary resection ...
The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis.
(Health and Medical Publications Group., 2010-12)
Boulle et al.(1) queried whether a clinical trial was needed to provide the evidence for the mortality benefits of antiretroviral therapy (ART) initiation during tuberculosis (TB) treatment. While several experts, including ...
Integration of antiretroviral therapy with tuberculosis treatment.
(Massachusetts Medical Society., 2011-10-20)
Background. We previously reported that integrating antiretroviral therapy (ART) with tuberculosis treatment reduces mortality. However, the timing for the initiation of ART during tuberculosis treatment remains ...
Managing multiple and extensively drug-resistant tuberculosis and HIV.
(Informa Healthcare., 2007)
Global increases in multi-drug-resistant and extensively drug-resistant tuberculosis (TB), are threatening both TB and HIV treatment programs worldwide. Together, they raise concerns of a global epidemic of untreatable TB. ...
Pregnancies complicated by multidrug-resistant tuberculosis and HIV co-infection in Durban, South Africa.
(International Union against Tuberculosis and Lung Disease., 2007)
SETTING: Tertiary hospitals in KwaZulu Natal, South Africa. OBJECTIVE: To study the impact of multidrug-resistant tuberculosis (MDR-TB) and human immunodeficiency virus-1 (HIV-1) co-infection during pregnancy on maternal ...
Timing of initiation of antiretroviral drugs during tuberculosis therapy.
(Massachusetts Medical Society., 2010)
Background. The rates of death are high among patients with coinfection with tuberculosis and the human immunodeficiency virus (HIV). The optimal timing for the initiation of antiretroviral therapy in relation to tuberculosis ...
Substitution of Moxifloxacin for Isoniazid during intensive phase treatment of Pulmonary Tuberculosis.
(American Thoracic Society., 2009-08-01)
Rationale: Moxifloxacin has potent activity against Mycobacterium tuberculosis in vitro and in a mouse model of antituberculosis (TB) chemotherapy, but data regarding its activity in humans are limited. Objectives: Our ...
Expanding HIV surveillance to include TB patients in resource-limited settings with a generalized epidemic.
(International Union against Tuberculosis and Lung Disease., 2009-12-01)
Screening of antenatal clinic attendees is central to monitoring the human immunodeficiency virus (HIV) epidemic. However, recent evidence suggests that declining fertility rates are affecting the reliability of antenatal ...
Re-inventing adherence : toward a patient-centered model of care for drug-resistant tuberculosis and HIV.
(International Union against Tuberculosis and Lung Disease., 2016)
Abstract available in PDF file.